Jay Backstrom Increases Stake in Agios Pharmaceuticals

Jay Backstrom, an insider at Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO), purchased 14,950 shares of the company on June 18, 2026. The transaction did not involve a pre-planned trading program. On the same day, shares of Agios traded at $35.47.

Insider Buying and Selling at Agios Pharmaceuticals, Inc.

Several insiders, including Jay Backstrom, acquired 14,950 shares each on June 18, 2026. Other insiders making similar purchases include Jacqualyn Fouse, David Scadden, and Rahul Ballal. Cynthia Smith and David Scadden also bought smaller amounts of 2,816 shares each. None of these transactions were part of Rule 10b5-1 trading plans.

Other Institutional Activity in Agios Pharmaceuticals

BlackRock, Inc. increased its holdings in Agios Pharmaceuticals by 519,528 shares, bringing its total to 5,754,957 shares valued at approximately $194.69 million. Farallon Capital Management LLC also boosted its stake by 524,495 shares, ending with 5,684,000 shares worth about $192.29 million. Meanwhile, D. E. Shaw & Co., Inc. significantly increased its position by 843,983 shares, resulting in a 45.9% increase to 2,681,169 shares valued at $90.70 million. On the other hand, Armistice Capital, LLC reduced its holdings by 320,000 shares, a 10.5% decrease, leaving them with 2,716,000 shares worth around $91.88 million.

Agios Pharmaceuticals, Inc. Stock Up 3.8%

As of Wednesday, shares of Agios Pharmaceuticals traded near $35.47. The company has a market capitalization of approximately $2.09 billion. Despite not being profitable, the stock has a beta of 0.587, indicating lower volatility compared to the market. Its 52-week trading range is between $22.24 and $46.00. The 50-day moving average stands at $29.03, while the 200-day moving average is $31.74. Agios boasts a strong liquidity position with a current ratio of 14.19 and a quick ratio of 12.80, alongside a low debt-to-equity ratio of 3.22.

Recent Earnings

Agios Pharmaceuticals reported revenue of $66.05 million with a modest growth rate of 1.38%. The company is not currently profitable, showing a negative return on equity of -32.81% and a net margin of zero. The next earnings release is scheduled for July 30, 2026.

Analysts Set New Price Targets

On June 11, 2026, JP Morgan maintained its hold rating on Agios Pharmaceuticals with a price target of $31. B of A Securities, on May 29, maintained its buy rating with a target of $40. Other analysts, like Truist Securities and HC Wainwright & Co., have set price targets ranging from $36 to $50. The consensus among eight analysts suggests a buy rating with an average target price of $40.75.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on discovering and developing medicines targeting cellular metabolism in the United States. The company's main product, PYRUKYND, is used for treating hemolytic anemias in adults with pyruvate kinase deficiency and is in clinical trials for other conditions. Agios is led by CEO Brian M. Goff and employs 539 people.

Bottom Line

Jay Backstrom's recent purchase of Agios Pharmaceuticals shares highlights insider confidence in the company's prospects. Investors often watch such insider transactions closely for signals about company health. While Agios is not currently profitable, its strong liquidity and ongoing drug development efforts make it a company to watch. Remember, insider transactions are disclosed after the fact and may not reflect the current position.